The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01): Report of interim analysis.
Mitsukuni Suenaga
No relevant relationships to disclose
Nobuyuki Mizunuma
No relevant relationships to disclose
Yoshiya Fujimoto
No relevant relationships to disclose
Masashi Ueno
No relevant relationships to disclose
Satoshi Matsusaka
No relevant relationships to disclose
Eiji Shinozaki
No relevant relationships to disclose
Yosuke Fukunaga
No relevant relationships to disclose
Satoshi Nagayama
No relevant relationships to disclose
Toshiharu Yamaguchi
No relevant relationships to disclose